Last reviewed · How we verify
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).
Details
| Lead sponsor | Allergan |
|---|---|
| Status | COMPLETED |
| Enrolment | 200 |
| Start date | 2014-07 |
| Completion | 2016-05 |
Conditions
- Macular Edema
Interventions
- dexamethasone 700 ㎍ intravitreal implant
Primary outcomes
- Maximum Change from Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — Baseline, 12 Months
- Percentage of Patients with a BCVA Improvement of ≥15 Letters in the Study Eye — Baseline, 12 Months
- Average Change from Baseline in BCVA in the Study Eye — Baseline, 12 Months
Countries
United States